CIC

MaaT Pharma Reports Cash and Revenues for Third Quarter 2022

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Kepler, Euronext Paris, Achievement, ANSM, Company, Digital, Society, IHMC, Maat, ARES, Agence nationale de sécurité du médicament et des produits de santé, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Salvage therapy, EUR, Drug design, IPO, Congress, EST, CGMP, Graft-versus-host disease, Survival, Forward-looking statement, Conference, Special access program, LSX, Annual general meeting, PICASSO, FDA, Biomarker, CIMON, Communication, Drug, ASH, R, Safety, CEO, Food, Showcase, EAP, Patient, Cancer, MET, Lymphatic system, CIC, UCSD Student-Run Free Clinic Project, Acute myeloid leukemia, International, Pharmaceutical industry, Film, Fine chemical

MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.
  • The net increase in cash over the third quarter of 2022 was EUR 1.9 million.
  • November 15-17, 2022 13th Annual Jefferies London Healthcare Conference London, UK: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Carole Schwintner, Chief Technology Officer of MaaT Pharma will attend the conference.
  • November 29, 2022 Investir day Paris, France: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Savita Bernal, Chief Business Officer of MaaT Pharma will attend the investor event.

Nordic pension funds want to increase climate investments in emerging markets and developing economies

Retrieved on: 
Wednesday, November 9, 2022
Climate Investment Funds, KLP, Varma Mutual Pension Insurance Company, COP27, Biodiversity, Nordic Council of Ministers, COP26, Nordic Council, Government, Private sector, Climate, Swiss Bank Employees' Union, PKA, Environment, Corporate responsibility, Chief executive officer, Commerce, Partnership, Pension fund, SL, Heart, USD, DFI, SPP, Greater Manchester Pension Fund, CEO, Pennsylvania State Employees' Retirement System, Travel, Chairperson, LSR, Policy, Investment, CIC, State, ATP, Initiative, Minister, Plant, Renewable energy, Bank, Insurance, Nordic

Insurance & Pension Denmark reported today thatDanish pension funds have invested US$9 billion in new clean energy investments since July 2021.

Key Points: 
  • Insurance & Pension Denmark reported today thatDanish pension funds have invested US$9 billion in new clean energy investments since July 2021.
  • This is also the case for new investments in emerging markets and developing economies, which are proving to be on track.
  • Kent Damsgaard, CEO, Insurance and Pension Denmark
    "Our current climate investments in emerging markets and developing countries are limited.
  • Committing pension funds in 2021: Almenni Pension Fund, ATP, Bank Employees' Pension Fund, The Pension Fund for Reykjavk City Employees, Birta Pension Fund, Br Pension Fund, Environment Agency Pension Fund, Festa Pension Fund, Frjlsi Pension Fund, Gildi Pension Fund, Greater Manchester Pension Fund, Ilmarinen, KLP, Lifsverk Pension Fund, Lv Group, LSR - Icelandic Pension Fund for State Employees, Merseyside Pension Fund, Nest Pension, Pension Fund of Commerce, Skandia, SL The General Pension Fund, SPP, Stapi Pension Fund, Storebrand Group, Varma Mutual Pension Insurance Company.

CYBER.ORG Range Announced Alongside Governor John Bel Edwards of Louisiana and Jen Easterly, Director of Cybersecurity and Infrastructure Security Agency (CISA) to Strengthen the Future U.S. Cybersecurity Workforce

Retrieved on: 
Monday, November 7, 2022
Technology, Security, Public Policy, Government, Other Education, Training, State, Local, Primary, Secondary, Education, Other Policy Issues, National Integrated Drought Information System, Range, National Initiative for Cybersecurity Education, Secretary of State of Louisiana, Curriculum, Workforce, DHS, Student, Learning, Education, CIC, United States Department of Homeland Security, Computer security, CISA, United States House Homeland Security Subcommittee on Cybersecurity, Infrastructure Protection and Innovation, Multimedia, CompTIA, Cybersecurity and Infrastructure Security Agency, Medical device, Tutoring, Medicine, Risk management

The CYBER.ORG Range is accessible to all K-12 students but is primarily geared toward high school students interested in learning core cybersecurity concepts and curriculum.

Key Points: 
  • The CYBER.ORG Range is accessible to all K-12 students but is primarily geared toward high school students interested in learning core cybersecurity concepts and curriculum.
  • Thanks to Louisiana Governor John Bel Edwards and Director Easterlys leadership, students can now more easily build confidence in cybersecurity and feel prepared to enter careers in a high-demand field.
  • Through the CYBER.ORG Range and CYBER.ORGs other free resources, K-12 teachers are empowered to teach cybersecurity in the classroom.
  • CYBER.ORG, through the CETAP grant provided by CISA, is doing critical work in Louisiana to advance the cybersecurity workforce, said Governor of Louisiana John Bel Edwards.

i-80 Gold Releases Results of a Scoping Study for the Ruby Hill Processing Plant

Retrieved on: 
Monday, November 7, 2022
Company, Order, Multimedia, Part, Gold, Industry, Contract, AACE, NYSE, PE, Terminology, GOLD, MTV 80s, Nature, TSX, EPCM, View, Forward-looking statement, Study, The Study, CIC, Mining, Carbon, Classification, Cost, NI, ROM, Uranium, Copper, Risk management, Granite Creek

The study was completed in two Parts to consider processing of oxide gold and/or base metal mineralization.

Key Points: 
  • The study was completed in two Parts to consider processing of oxide gold and/or base metal mineralization.
  • "With appreciable oxide mineralization having been identified at both Ruby Hill and Granite Creek, we felt it was prudent to assess the possible restart of the Ruby Hill CIL Plant as a second Company operated processing facility.
  • We plan to incorporate the results of this work in our planned upcoming economic studies being completed for Granite Creek and Ruby Hill."
  • The Scoping Study is not definitive and subject to further study by the Company and not specifically based on material from the Company's Projects but generic in nature.

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
Thursday, November 3, 2022
Patient, Pantetheine, Propionic acidemia, Compliance, Manufacturing execution system, Congenital disorders of amino acid metabolism, SBS, Respiration (physiology), Short bowel syndrome, GLOBE, FDA, Safety, PS, COVID-19, Nasdaq, Stoma, Study, Degenerative disease, STARS, Failure, U.S. Securities and Exchange Commission, Community of Metros, Forward-looking statement, Partnership, Drug development, Phrase, CIC, MMA, Security (finance), Coenzyme A, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s Phase 3 STARS (STudy of ApRglutide in SBS) pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Key Points: 
  • This result is a testament to a successful operational effort based on our strong partnership with patients and investigators involved in this study.
  • STARS is a pivotal, global Phase 3 study enrolling approximately 144 patients with SBS-IF stratified 50/50 for CIC and stoma, with patients being evaluated over 48 weeks and 24 weeks respectively.
  • The study includes an improved PS weaning algorithm tailored to remnant bowel anatomy to enhance signal detection.
  • STARS is designed to establish a new standard of care for all patients with SBS-IF and to tailor apraglutide treatment to patients with distinct remnant bowel anatomy.

Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

Retrieved on: 
Tuesday, November 1, 2022
Infection, Health, Royal commission, Omicron, COVID-19, WHO, European Commission, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NVAX, Novavax, Review, Genetic engineering, CIC, Food, Nanoparticle, Global health, Biotechnology, Clothing, Vaccine

The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.

Key Points: 
  • The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.
  • The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the WHO.
  • The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional populations and indications such as adolescents and as a booster.
  • These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

In New Advanced Testing, UV Angel Clean Air™ Purification Systems Proven to Reduce 99.9 Percent of Aerosolized Variants of SARS CoV2, the Virus That Causes COVID-19

Retrieved on: 
Wednesday, October 26, 2022
COVID-19, Technology, Medical Supplies, Infectious Diseases, Hospitals, Other Technology, Health Technology, Software, Health, Linda, National Institute, CDC, Bulgarian–American Joint Military Facilities, Risk, Government, White House, Virus, Infection, Education, Society, Patient, BSL 3, Fungus, HVAC, Restaurant, MBA, White, Research, National Institute for Occupational Safety and Health, Science, Occupational safety and health, ASHRAE, Technology, Center, CIC, Medical Affairs Bureau, UVGI, CEO, Safety, Bacteria, United States Environmental Protection Agency, Environment, Korea Disease Control and Prevention Agency, Nursing, EPA, SARS, Atmosphere, COVID-19, Â, Ultraviolet, School, NIOSH, Vaccine, Heating, ventilation, and air conditioning, Health

The results from this study were provided by a third-party BSL 3 laboratory qualified to test for the aerosolized SARS CoV2 virus and its associated variants.

Key Points: 
  • The results from this study were provided by a third-party BSL 3 laboratory qualified to test for the aerosolized SARS CoV2 virus and its associated variants.
  • UV Angel tests its air products with actual aerosolized (airborne) viruses, unlike other technologies which only test on surfaces.
  • Through innovation in automated disinfection technologies, UV Angel works to protect frontline healthcare workers, staff, patients, and families by helping to reduce healthcare associated infections, said Tom Byrne, CEO of UV Angel.
  • Utilizing a chemical free approach, UV Angel Clean Air units are designed to fit directly into a traditional ceiling light fixture.

Cleo Earns G2 Fall 2022 Distinctions for Leader in EDI and MFT

Retrieved on: 
Tuesday, October 25, 2022
Networks, Internet, Data Management, Technology, Software, Transfer, Cloud, API, Leadership, Movement, Computer, Electronic data interchange, EDI, MFT, CIC, Ecosystem, Potter Leader-Enterprise, Solution, Online shopping, Video game console, G2

As part of the G2s Fall 2022 report, Cleo garnered honors across Electronic Data Interchange (EDI), Managed File Transfer (MFT), and On-Premise Data integration.

Key Points: 
  • As part of the G2s Fall 2022 report, Cleo garnered honors across Electronic Data Interchange (EDI), Managed File Transfer (MFT), and On-Premise Data integration.
  • In the EDI category, Cleo won awards including Leader Enterprise, Leader Mid-Market, and Best Relationships Mid-Market.
  • Cleo was also noted as Leader MFT and Leader On-Premise Data Integration.
  • These accolades are the result of G2 user reviews praising Cleos innovative, cloud-based ecosystem integration platform, Cleo Integration Cloud (CIC).

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

Retrieved on: 
Thursday, October 20, 2022
Pharmaceutical, Fitness & Nutrition, Health, Other Health, LinkedIn, Constipation, Webcast, Investor, Ironwood Pharmaceuticals, Patient, Gastrointestinal disease, Standard of care, Twitter, GI, Nasdaq, History, Software, CIC, Irritable bowel syndrome, Medication, Heart, IBS-C, Pharmaceutical industry

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022.
  • The call will be available for replay via telephone starting Thursday, November 3, 2022 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 17, 2022.
  • To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230.
  • Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

Cleo, VAI Expand Partnership to Accelerate Ecosystem Integration Adoption

Retrieved on: 
Wednesday, October 19, 2022
Software, Supply Chain Management, Networks, Other Retail, Internet, Data Management, Technology, Other Manufacturing, Retail, Transport, Other Technology, Logistics, Supply Chain Management, Manufacturing, Cloud, VAI, API, Movement, ERP, Growth, EDI, LLC, Organization, Intelligence, Business, Multimedia, Improper integral, Partnership, CIC, Industry, Medication, Ecosystem, Business development, Cleo, Calendar, Solution, Online shopping, Video game console, Renewable energy, Sales, Food

VAI , a leading Enterprise Resource Planning (ERP) software developer, and Cleo , the pioneer and global leader of the Ecosystem Integration software category, jointly announced they are expanding their longtime partnership to help mutual customers in key industries migrate B2B integration solutions to the cloud.

Key Points: 
  • VAI , a leading Enterprise Resource Planning (ERP) software developer, and Cleo , the pioneer and global leader of the Ecosystem Integration software category, jointly announced they are expanding their longtime partnership to help mutual customers in key industries migrate B2B integration solutions to the cloud.
  • While the relationship originally revolved around VAI serving as a reseller for Cleos traditional on-prem integration solutions, VAI has now joined Cleos rapidly expanding System Integrator partner program to begin assisting the duos more than 80 joint customers in their migration to the Cleo Integration Cloud platform, a cloud-based B2B integration solution.
  • By expanding our partnership with Cleo, we stand ready to arm all our valued customers with the ecosystem integration solutions they need to outsmart supply chain disruption by implementing the integration solutions todays disruptive markets require.
  • Cleo Integration Cloud (CIC) is a cloud-based integration platform, purpose-built to design, build, operate and optimize critical ecosystem integration processes.